<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310036</url>
  </required_header>
  <id_info>
    <org_study_id>ML25637</org_study_id>
    <nct_id>NCT01310036</nct_id>
  </id_info>
  <brief_title>A Study of Tarceva (Erlotinib) as First Line Therapy in Patients With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations</brief_title>
  <official_title>An Open-label Multi-center Study of Erlotinib (TarcevaÂ®) as First Line Therapy Until and Beyond Disease Progression in NSCLC Patients Who Harbour EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, single arm study will evaluate the safety and efficacy of Tarceva
      (erlotinib) as first-line therapy in patients with stage IV or recurrent non-small cell lung
      cancer who harbour epidermal growth factor receptor (EGFR) mutations. All patients will
      receive Tarceva 150 mg daily orally until disease progression or unacceptable toxicity
      occurs. At the investigator's discretion, patients may receive Tarceva beyond disease
      progression.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival by RECIST (PFS1), defined as time from first dose until documented RECIST disease progression or death of any cause at any time, whichever occurs first</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by investigator's discretion (PFS2), defined as time from first study dose to off-Tarceva PD assessed by investigator based on overall clinical evaluation not limited to RECIST</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (all patients and patients with EGFR mutation E19del or L858R)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (all patients and patients with EGFR mutation E19del or L858R)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (patients with EGFR mutation E19del or L858R)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (all patients and patients with EGFR mutation E19del or L858R)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between EGFR mutations in plasma and clinical outcome (ORR/PFS/OS)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Non-Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib [Tarceva]</intervention_name>
    <description>150 mg orally daily</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Stage IV or recurrent non-small cell lung cancer (NSCLC)

          -  Presence of mutation(s) in exon 18 through exon 21 of epidermal growth factor
             receptor (EGFR), (except T790M single mutation only)

          -  Measurable disease (at least one lesion &gt;= 10 mm in longest diameter)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate hematological, renal and liver function

        Exclusion Criteria:

          -  Patients with T790M single mutation only

          -  Prior exposure to agents directed at the human epidermal receptor (HER) axis, e.g.
             erlotinib, gefitinib, cetuximab, trastuzumab

          -  Prior chemotherapy or systemic anti-cancer therapy for advanced NSCLC disease

          -  Symptomatic or uncontrolled central nervous system (CNS) metastases

          -  Other malignancy within the last 5 years, except for carcinoma in situ of the cervix,
             or basal or squamous cell carcinoma of the skin, or surgically treated localized
             prostate cancer, or surgically treated ductal cell carcinoma in situ of the breast

          -  Any significant ophthalmologic abnormality

          -  Pre-existing parenchymal lung disease such as pulmonary fibrosis

          -  Use of coumarins (for anti-coagulation therapy the use of low molecular weight
             heparin is recommended instead)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>00833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>February 18, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
